Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Tingting Pan, Shiyu Han, Meng Zhou, Jiaqian Qi, Hong Wang, Xiaoyan Xu, Xueqian Li, Yifang Yao & Yue Han. (2022) Efficacy of azacitidine in preventing relapse after hematopoietic stem cell transplantation for advanced myeloid malignancies: a systematic review and meta-analysis. Expert Review of Hematology 15:5, pages 457-464.
Read now
Read now
Jonathan A. Webster, Meera Yogarajah, Marianna Zahurak, Heather Symons, Amy E. Dezern, Ivana Gojo, Gabrielle T. Prince, Jillian Morrow, Richard J. Jones, B. Douglas Smith & Margaret Showel. (2021) A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia & Lymphoma 62:13, pages 3181-3191.
Read now
Read now
Naveed Ali, Benjamin Tomlinson, Leland Metheny, Steven C. Goldstein, Pingfu Fu, Shufen Cao, Paolo Caimi, Rushang D. Patel, Juan Carlos Varela, Luisa Andrade, Jason W. Balls, Linda Baer, Megan Smith, Tori Smith, Megan Nelson, Marcos de Lima & Shahram Mori. (2020) Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia & Lymphoma 61:12, pages 2839-2849.
Read now
Read now
Articles from other publishers (22)
Qingya Wang, Zeyin Liang, Hanyun Ren, Yujun Dong, Yue Yin, Qingyun Wang, Wei Liu, Bingjie Wang, Na Han, Yangliu Li & Yuan Li. (2023) Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation. Annals of Hematology.
Crossref
Crossref
Yuho Najima. (2023) Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS. International Journal of Hematology 118:2, pages 169-182.
Crossref
Crossref
Eshrak AL-Shaibani, Igor Novitzky-Basso, Jonas Mattsson & Dennis Dong Hwan Kim. (2023) Post-transplant maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation harmonizing multiple therapeutic modalities including targeted therapy, immunotherapy and cellular therapy. International Journal of Hematology 118:1, pages 1-17.
Crossref
Crossref
Yimei Feng, Ting Chen, Yun Zhang, Han Yao, Ping Wang, Lu Wang, Kaniel Cassady, Zhongmin Zou, Yuqing Liu, Lu Zhao, Lei Gao, Xi Zhang & Peiyan Kong. (2023) Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia. Frontiers in Immunology 14.
Crossref
Crossref
Rodrick Babakhanlou & Farhad Ravandi-Kashani. (2022) SOHO State of the Art Updates and Next Questions |The Role of Maintenance Therapy in Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Crossref
David Beauvais, Kévin-James Wattebled, Elodie Drumez & Ibrahim Yakoub-Agha. (2022) Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis. Frontiers in Medicine 9.
Crossref
Crossref
Katherine Tarlock, Maria Luisa Sulis, Joseph H. Chewning, Jessica A. Pollard, Todd Cooper, Alan Gamis, Shalini Shenoy, Matthew Kutny, John Horan, Soheil Meshinchi, Jaap-Jan Boelens, Marie Bleakley, Paul A. Carpenter & E. Anders Kolb. (2022) Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy 28:9, pages 530-545.
Crossref
Crossref
Firas Kreidieh, Iman Abou Dalle, Nour Moukalled, Jean El-Cheikh, Eolia Brissot, Mohamed Mohty & Ali Bazarbachi. (2022) Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. International Journal of Hematology 116:3, pages 330-340.
Crossref
Crossref
Kevin-James Wattebled, Elodie Drumez, Valérie Coiteux, Léonardo Magro, Micha Srour, Paul Chauvet, Bruno Quesnel, Alain Duhamel, Ibrahim Yakoub-Agha & David Beauvais. (2022) Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation. Annals of Hematology 101:6, pages 1321-1331.
Crossref
Crossref
Smith Kungwankiattichai, Ben Ponvilawan, Claudie Roy, Pattaraporn Tunsing, Florian Kuchenbauer & Weerapat Owattanapanich. (2022) Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis. Frontiers in Medicine 9.
Crossref
Crossref
Evgenii Shumilov, Inna Shakhanova, Johanna Flach, Nicole Schmidt, Susanne Buerki, Myriam Legros, Marie-Noëlle Kronig, Yishai Ofran, Sabine Gerull, Michael Medinger, Behrouz Mansouri Taleghani, Jakob Passweg, Jörg Halter, Ulrike Bacher & Thomas Pabst. (2021) Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. Bone Marrow Transplantation 57:2, pages 224-231.
Crossref
Crossref
Jonathan A. Webster, Leo Luznik & Ivana Gojo. (2021) Treatment of AML Relapse After Allo-HCT. Frontiers in Oncology 11.
Crossref
Crossref
Li Xuan & Qifa Liu. (2021) Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Jan Philipp Bewersdorf, Martin S. Tallman & Maximilian Stahl. (2021) Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Current Opinion in Oncology 33:6, pages 658-669.
Crossref
Crossref
Andriyana K. Bankova, Wendy Pang, Brenda Josefina Velasco, Janel R. Long-Boyle & Judith A. Shizuru. (2021) 5-Azacytidine depletes hematopoietic stem cells and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Blood Advances.
Crossref
Crossref
Firas El Chaer, Uma BorateRémy Duléry, Shernan G. Holtan, Arjun Datt Law, Lori Muffly, Samah NassereddineRory M. Shallis, Kate StringarisJustin Taylor, Steven M. Devine, Mohamad MohtyChristopher S. Hourigan. (2021) Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. Blood Advances 5:6, pages 1757-1759.
Crossref
Crossref
Amany R. Keruakous, Jennifer Holter-Chakrabarty, Sarah A. Schmidt, Mohamad O. Khawandanah, George Selby & Carrie Yuen. (2021) Azacitidine maintenance therapy post-allogeneic stem cell transplantation in poor-risk acute myeloid leukemia. Hematology/Oncology and Stem Cell Therapy.
Crossref
Crossref
Bhagirathbhai Dholaria, Bipin N. Savani, Betty K. Hamilton, Betul Oran, Hien D. Liu, Martin S. Tallman, Stefan Octavian Ciurea, Noa G. Holtzman, Gordon L. Phillips II, Steven M. Devine, Gabriel Mannis, Michael R. Grunwald, Frederick Appelbaum, Cesar Rodriguez, Firas El Chaer, Nina Shah, Shahrukh K. Hashmi, Mohamed A. Kharfan-Dabaja, Zachariah DeFilipp, Mahmoud Aljurf, AlFadel AlShaibani, Yoshihiro Inamoto, Tania Jain, Navneet Majhail, Miguel-Angel Perales, Mohamad Mohty, Mehdi Hamadani, Paul A. Carpenter & Arnon Nagler. (2021) Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Transplantation and Cellular Therapy 27:1, pages 6-20.
Crossref
Crossref
Kathryn A. Culos, Katie S. Gatwood & Michael Byrne. (2020) Maintenance Strategies After Hematopoietic Cell Transplantation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40:8, pages 727-740.
Crossref
Crossref
Andrew Kent, Sumithira Vasu, Derek Schatz, Natalie Monson, Steven Devine, Clayton Smith, Jonathan A. Gutman & Daniel A. Pollyea. (2020) Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse. Blood Advances 4:13, pages 3102-3108.
Crossref
Crossref
Matteo Molica, Massimo Breccia, Roberto Foa, Elias Jabbour & Tapan M. Kadia. (2019) Maintenance therapy in AML: The past, the present and the future. American Journal of Hematology 94:11, pages 1254-1265.
Crossref
Crossref
Ravi Vij, Jennifer Le-Rademacher, Kristina Laumann, Vera Hars, Kouros Owzar, Tsiporah Shore, Sumithira Vasu, Amanda Cashen, Luis Isola, Thomas Shea, Margarida DeMagalhaes-Silverman, David Hurd, Kenneth Meehan, Frank Beardell & Steven Devine. (2019) A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). Biology of Blood and Marrow Transplantation 25:10, pages 1984-1992.
Crossref
Crossref